Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Sufficiency for inducible Caspase-9 safety switch in human pluripotent stem cells and disease cells

Abstract

Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) have promising potential for opening new avenues in regenerative medicine. However, since the tumorigenic potential of undifferentiated pluripotent stem cells (PSCs) is a major safety concern for clinical transplantation, inducible Caspase-9 (iC9) is under consideration for use as a fail-safe system. Here, we used targeted gene editing to introduce the iC9 system into human iPSCs, and then interrogated the efficiency of inducible apoptosis with normal iPSCs as well as diseased iPSCs derived from patients with acute myeloid leukemia (AML-iPSCs). The iC9 system induced quick and efficient apoptosis to iPSCs in vitro. More importantly, complete eradication of malignant cells without AML recurrence was shown in disease mouse models by using AML-iPSCs. In parallel, it shed light on several limitations of the iC9 system usage. Our results suggest that careful use of the iC9 system will serve as an important countermeasure against posttransplantation adverse events in stem cell transplantation therapies.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Correlation between inducible caspase-9 (iC9) expression and induced apoptosis kinetics.
Fig. 2: Induced apoptosis in AML mouse model.

References

  1. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–72.

    Article  CAS  Google Scholar 

  2. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282:1145–7.

    Article  CAS  Google Scholar 

  3. Nori S, Okada Y, Nishimura S, Sasaki T, Itakura G, Kobayashi Y, et al. Long-term safety issues of iPSC-based cell therapy in a spinal cord injury model: oncogenic transformation with epithelial-mesenchymal transition. Stem Cell Rep. 2015;4:360–73.

    Article  CAS  Google Scholar 

  4. Ando M, Nishimura T, Yamazaki S, Yamaguchi T, Kawana-Tachikawa A, Hayama T, et al. A safeguard system for induced pluripotent stem cell-derived rejuvenated T cell therapy. Stem Cell Rep. 2015;5:597–608.

    Article  CAS  Google Scholar 

  5. Itakura G, Kawabata S, Ando M, Nishiyama Y, Sugai K, Ozaki M, et al. Fail-safe system against potential tumorigenicity after transplantation of iPSC derivatives. Stem Cell Rep. 2017;8:673–84.

    Article  CAS  Google Scholar 

  6. Takashima Y, Guo G, Loos R, Nichols J, Ficz G, Krueger F, et al. Resetting transcription factor control circuitry toward ground-state pluripotency in human. Cell. 2014;158:1254–69.

    Article  CAS  Google Scholar 

  7. Chao MP, Gentles AJ, Chatterjee S, Lan F, Reinisch A, Corces MR, et al. Human AML-iPSCs reacquire leukemic properties after differentiation and model clonal variation of disease. Cell Stem Cell. 2017;20:329–44e7.

    Article  CAS  Google Scholar 

  8. Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Goto H, Zhu D, et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell. 2013;12:114–26.

    Article  CAS  Google Scholar 

  9. Miyazaki T, Isobe T, Nakatsuji N, Suemori H. Efficient adhesion culture of human pluripotent stem cells using laminin fragments in an uncoated manner. Sci Rep. 2017;7:41165.

    Article  CAS  Google Scholar 

  10. Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc. 2007;2:3081–9.

    Article  CAS  Google Scholar 

  11. Kuchimaru T, Iwano S, Kiyama M, Mitsumata S, Kadonosono T, Niwa H, et al. A luciferin analogue generating near-infrared bioluminescence achieves highly sensitive deep-tissue imaging. Nat Commun. 2016;7:11856.

    Article  CAS  Google Scholar 

  12. Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP, et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol. 2011;29:731–4.

    Article  CAS  Google Scholar 

  13. Qin JY, Zhang L, Clift KL, Hulur I, Xiang AP, Ren BZ, et al. Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS ONE. 2010;5:e10611.

    Article  Google Scholar 

  14. Iwano S, Sugiyama M, Hama H, Watakabe A, Hasegawa N, Kuchimaru T, et al. Single-cell bioluminescence imaging of deep tissue in freely moving animals. Science. 2018;359:935–9.

    Article  CAS  Google Scholar 

  15. Kim SI, Oceguera-Yanez F, Sakurai C, Nakagawa M, Yamanaka S, Woltjen K. Inducible transgene expression in human iPS cells using versatile all-in-one piggyBac transposons. Methods Mol Biol. 2016;1357:111–31.

    Article  CAS  Google Scholar 

  16. Park MA, Jung HS, Slukvin I. Genetic engineering of human pluripotent stem cells using PiggyBac transposon system. Curr Protoc Stem Cell Biol. 2018;47:e63.

    Article  Google Scholar 

  17. Ding S, Wu X, Li G, Han M, Zhuang Y, Xu T. Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell. 2005;122:473–83.

    Article  CAS  Google Scholar 

  18. Ordovas L, Boon R, Pistoni M, Chen Y, Wolfs E, Guo W, et al. Efficient recombinase-mediated cassette exchange in hPSCs to study the hepatocyte lineage reveals AAVS1 locus-mediated transgene inhibition. Stem Cell Rep. 2015;5:918–31.

    Article  CAS  Google Scholar 

  19. Wu C, Hong SG, Winkler T, Spencer DM, Jares A, Ichwan B, et al. Development of an inducible caspase-9 safety switch for pluripotent stem cell-based therapies. Mol Ther Methods Clin Dev. 2014;1:14053.

    Article  Google Scholar 

  20. Yagyu S, Hoyos V, Del Bufalo F, Brenner MK. Multiple mechanisms determine the sensitivity of human-induced pluripotent stem cells to the inducible caspase-9 safety switch. Mol Ther Methods Clin Dev. 2016;3:16003.

    Article  Google Scholar 

  21. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365:1673–83.

    Article  Google Scholar 

  22. Rong Z, Fu X, Wang M, Xu Y. A scalable approach to prevent teratoma formation of human embryonic stem cells. J Biol Chem. 2012;287:32338–45.

    Article  CAS  Google Scholar 

  23. Martin RM, Fowler JL, Cromer MK, Lesch BJ, Ponce E, Uchida N, et al. Improving the safety of human pluripotent stem cell therapies using genome-edited orthogonal safeguards. Nat Commun. 2020;11.

  24. Liu M, Maurano MT, Wang H, Qi H, Song CZ, Navas PA, et al. Genomic discovery of potent chromatin insulators for human gene therapy. Nat Biotechnol. 2015;33:198–203.

    Article  Google Scholar 

  25. Iuliucci JD, Oliver SD, Morley S, Ward C, Ward J, Dalgarno D, et al. Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J Clin Pharmacol. 2001;41:870–9.

    Article  CAS  Google Scholar 

  26. Kasinathan N, Jagani HV, Alex AT, Volety SM, Rao JV. Strategies for drug delivery to the central nervous system by systemic route. Drug Deliv. 2015;22:243–57.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Miki Ando and Motoo Watanabe (The University of Tokyo) for helpful discussions; Atsushi Miyawaki and Satoshi Iwano (RIKEN) for kindly providing AkaLuc gene and Akalumine-HCl (TokeOni); and Austin Smith and Yasuhiro Takashima (University of Cambridge) for kindly providing PiggyBac donor and transposase plasmids.

Funding

The project was supported in part by a grant from California Institute for Regenerative Medicine (CIRM; LA1_C12-06917, QUEST DISC2-08874), Weston Havens Foundation, and a research fellowship from Japan Society for the Promotion of Science (JSPS).

Author information

Authors and Affiliations

Authors

Contributions

Conceptualization: TN; methodology: TN, HX, and MI; investigation: TN, HX, MI, DK, BS, YT, FPS, and SM; resources: RMM, MO, MN, SRB, MLC, and RM; writing—original draft: TN, HX, and HN; writing—review and editing: TN, HX, FPS, and HN; funding acquisition: TN and HN; and supervision: TN, AS, and HN.

Corresponding authors

Correspondence to Toshinobu Nishimura or Hiromitsu Nakauchi.

Ethics declarations

Conflict of interest

RM is a co-founder, equity holder, and serves on the Board of Directors of Forty Seven, Inc. HN is a co-founder, member of the scientific advisory board, and shareholder of Megakaryon Corp., iCELL, Inc. and Century Therapeutics, LLC. The remaining authors declare no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nishimura, T., Xu, H., Iwasaki, M. et al. Sufficiency for inducible Caspase-9 safety switch in human pluripotent stem cells and disease cells. Gene Ther 27, 525–534 (2020). https://doi.org/10.1038/s41434-020-0179-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41434-020-0179-z

Search

Quick links